NASDAQ:CRVO CervoMed (CRVO) Stock Price, News & Analysis $15.13 -0.18 (-1.18%) (As of 09/27/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get CervoMed alerts: Email Address About CervoMed Stock (NASDAQ:CRVO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CervoMed alerts:Sign Up Key Stats Today's Range$14.52▼$15.6450-Day Range$10.63▼$18.6252-Week Range$4.45▼$26.38Volume74,117 shsAverage Volume52,346 shsMarket Capitalization$93.35 millionP/E RatioN/ADividend YieldN/APrice Target$53.60Consensus RatingBuy Company OverviewCervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.Read More… NOTICE: You have until Tuesday, November 19th (Ad)On Tuesday, November 19, 2024 smart investors will collect their share of a $1.2 billion windfall... It's part of a unique strategy which has nothing to do with risky investments like options, cryptos or forex. And while it might sound crazy...Click here for the ticker >>> CervoMed Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks25th Percentile Overall ScoreCRVO MarketRank™: CervoMed scored higher than 25% of companies evaluated by MarketBeat, and ranked 878th out of 995 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingCervoMed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCervoMed has only been the subject of 4 research reports in the past 90 days.Read more about CervoMed's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for CervoMed are expected to decrease in the coming year, from ($1.45) to ($2.60) per share.Price to Book Value per Share RatioCervoMed has a P/B Ratio of 11.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about CervoMed's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted21.50% of the float of CervoMed has been sold short.Short Interest Ratio / Days to CoverCervoMed has a short interest ratio ("days to cover") of 12.7, which indicates bearish sentiment.Change versus previous monthShort interest in CervoMed has recently increased by 7.48%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCervoMed does not currently pay a dividend.Dividend GrowthCervoMed does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted21.50% of the float of CervoMed has been sold short.Short Interest Ratio / Days to CoverCervoMed has a short interest ratio ("days to cover") of 12.7, which indicates bearish sentiment.Change versus previous monthShort interest in CervoMed has recently increased by 7.48%, indicating that investor sentiment is decreasing significantly. News and Social Media2.8 / 5News Sentiment0.97 News SentimentCervoMed has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for CervoMed this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for CRVO on MarketBeat in the last 30 days. This is a decrease of -94% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added CervoMed to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CervoMed insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.00% of the stock of CervoMed is held by insiders.Percentage Held by InstitutionsOnly 25.15% of the stock of CervoMed is held by institutions.Read more about CervoMed's insider trading history. Receive CRVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CervoMed and its competitors with MarketBeat's FREE daily newsletter. Email Address CRVO Stock News HeadlinesCervoMed to Deliver Late-Breaking Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)September 27 at 2:01 PM | tmcnet.comEquities Analysts Offer Predictions for CervoMed Inc.'s FY2024 Earnings (NASDAQ:CRVO)September 24, 2024 | americanbankingnews.comMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.September 28, 2024 | Paradigm Press (Ad)With 35% ownership, insiders at CervoMed Inc. (NASDAQ:CRVO) are pretty optimistic and have been buying recentlySeptember 21, 2024 | finance.yahoo.comCervoMed (NASDAQ:CRVO) Now Covered by Chardan CapitalSeptember 20, 2024 | americanbankingnews.comCervoMed Inc. (NASDAQ:CRVO) Short Interest Up 5.9% in AugustSeptember 19, 2024 | americanbankingnews.comChardan Capital Initiates Coverage of CervoMed (CRVO) with Buy RecommendationSeptember 19, 2024 | msn.comCervoMed to Participate in Upcoming Investor ConferencesAugust 27, 2024 | globenewswire.comSee More Headlines CRVO Stock Analysis - Frequently Asked Questions How have CRVO shares performed this year? CervoMed's stock was trading at $7.63 at the beginning of the year. Since then, CRVO stock has increased by 98.3% and is now trading at $15.13. View the best growth stocks for 2024 here. How were CervoMed's earnings last quarter? CervoMed Inc. (NASDAQ:CRVO) announced its earnings results on Monday, August, 12th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by $0.03. The business earned $3.29 million during the quarter, compared to the consensus estimate of $3.48 million. CervoMed had a negative net margin of 52.24% and a negative trailing twelve-month return on equity of 27.91%. Who are CervoMed's major shareholders? Top institutional shareholders of CervoMed include Armistice Capital LLC (10.37%), Renaissance Technologies LLC (0.52%), Citizens Financial Group Inc. RI (0.44%) and Bank of New York Mellon Corp (0.22%). How do I buy shares of CervoMed? Shares of CRVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Last Earnings8/12/2024Today9/28/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CRVO Previous SymbolNASDAQ:CRVO CUSIPN/A CIK1053691 Webdiffusionpharma.com Phone14342200718Fax434-220-0722Employees4Year FoundedN/APrice Target and Rating Average Stock Price Target$53.60 High Stock Price Target$65.00 Low Stock Price Target$35.00 Potential Upside/Downside+254.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-2,170,000.00 Net Margins-52.24% Pretax Margin-52.24% Return on Equity-27.91% Return on Assets-24.25% Debt Debt-to-Equity RatioN/A Current Ratio14.73 Quick Ratio14.73 Sales & Book Value Annual Sales$7.14 million Price / Sales13.07 Cash FlowN/A Price / Cash FlowN/A Book Value$1.30 per share Price / Book11.64Miscellaneous Outstanding Shares6,170,000Free Float6,047,000Market Cap$93.35 million OptionableNot Optionable Beta1.60 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report This page (NASDAQ:CRVO) was last updated on 9/28/2024 by MarketBeat.com Staff From Our PartnersThe Bible Says it Clear As DayIt came to me clear-as-day thanks to the Bible… in the Parable of Talents, in the book of Matthew… This pa...Prosperity Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredIt’s over.We found a tiny company which provides the backbone for the entire $15.7 trillion AI industry... It's used ...Behind the Markets | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe most serious warning of my careerWith the 2024 election just weeks away, a new crisis is barrelling down on America… one that could cleave the ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CervoMed Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CervoMed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.